drugset / Trial / NCT04796324
Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
NaSingle-groupOpen-labelTreatment
Summary
The purpose is to investigate anti-tumor effect of ixabepilone in patients with locally recurrent or metastatic breast cancer (mBC) selected by the Ixabepilone DRP after failure of an anthracycline and taxanes.
Timeline
- Start
- 2021-03-01
- Primary completion
- 2024-12-01
- Completion
- 2025-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixabepilone | Small molecule | 40 mg/m2 | Intravenous |